Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881181 | 0.90 | MAPK1 (0.39) | CYP1A2CYP2D6MAOAACHEMAPK1 | |
| SCHEMBL3885397 | 0.83 | MAPK1 (0.40) | CYP1A2CYP2D6MAOAACHEMAPK1 | |
| SCHEMBL5182469 | 0.79 | NR4A2 (0.35) | CACNA1HCACNA1BMAOBLSSMAPK1 | |
| SCHEMBL4035884 | 0.78 | CACNA1H (0.36) | CACNA1HCACNA1BCYP1A2CYP2D6MAOB | |
| Hydrochloric Acid SCHEMBL4038349 | 0.77 | CACNA1H (0.35) | CACNA1HCACNA1BCYP1A2CYP2D6MAOB | |
| SCHEMBL4849242 | 0.76 | CACNA1B (0.36) | CACNA1HCACNA1BCYP1A2CYP2D6MAOB | |
| SCHEMBL5227001 | 0.75 | MAOB (0.36) | CACNA1HCACNA1BCYP1A2CYP2D6MAOB | |
| SCHEMBL3881168 | 0.74 | MAPK1 (0.38) | CACNA1BCYP1A2CYP2D6MAPK1CHRM2 | |
| SCHEMBL5181121 | 0.74 | MAPK1 (0.39) | MAPK1CHRM2HTR1AADRA2ADRD1 | |
| SCHEMBL6322406 | 0.74 | CACNA1B (0.39) | CACNA1HCACNA1BCYP1A2CYP2D6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684742-B1 | USE OF 1-OXADIBENZO [E,H] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-01-14 | — | — | EP | claimed |
| US-20070173493-A1 | 1-Oxadibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| US-20050209214-A1 | 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| US-20050148577-A1 | 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| EP-1506204-A2 | 1-OXA-DIBENZOAZULENES AS INHIBITORS OF TUMOR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | Pliva - Istrazivacki Institut d.o.o. (HR) | 2005-02-16 | — | — | EP | claimed |
| WO-2003097649-A2 | 1-OXA-DIBENZOAZULENES AS INHIBITORS OF TUMOR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-11-27 | — | — | WO | claimed |
| US-20070173493-A1 | 1-Oxadibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| US-20050148577-A1 | 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148577-A1 | 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1B, IL1A | CACNA1H 1889/4885CACNA1B 2114/4885CYP1A2 643/4885 |
| US-20050209214-A1 | 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1B, IL1A | CACNA1H 1897/4885CACNA1B 2137/4885CYP1A2 567/4885 |
| US-20070173493-A1 | 1-Oxadibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, MAOB, BCHE | CACNA1H 319/4885CACNA1B 611/4885CYP1A2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.